AI企业Anthropic证实正在运营一个生物实验室，用于开展AI驱动的生物学实验1。公司首席执行官Dario Amodei表示，"我相信AI可在5-10年内治愈大多数重大疾病"1。为支撑这一方向，Anthropic于4月收购了隐形生物技术公司Coefficient Bio1，同时宣布与药企Novo Nordisk达成联合药物发现协议1。
Anthropic生命科学负责人Eric Kauderer-Abrams指出，"生物学最终的测试仍然是，而且在一段时间内仍将是真实的实验室工作"1。为推进这一计划，该公司推出了生命科学验证计划，为经过审核的生物研究人员提供其最强大AI模型的访问权限1。不过，这些进展与公司在AI安全上的立场形成了反差——Anthropic对齐负责人曾给出AI在未来十年内灭绝人类的概率大于10%1，而CEO Dario Amodei也于最近呼吁业界放缓步伐并实施自我监管1。
Anthropic has confirmed it operates a laboratory conducting biology experiments powered by artificial intelligence, marking a significant expansion into the life sciences sector.1 The company acquired stealth biotech firm Coefficient Bio in April and has simultaneously announced a joint drug discovery partnership with Novo Nordisk.1 Additionally, Anthropic launched a Life Sciences Validation Program that grants vetted biology researchers access to its most advanced AI models.1
The initiative aligns with ambitious claims from Anthropic CEO Dario Amodei, who stated: "I believe AI can cure most major diseases within 5-10 years."1 Eric Kauderer-Abrams, who leads Anthropic's life sciences efforts, emphasized the continued importance of physical experimentation, noting: "Biology's ultimate test remains, and will remain for some time, actual lab work."1
The company's move into biotechnology stands in contrast to its public warnings about AI safety risks. Anthropic's alignment lead has estimated the probability of AI causing human extinction within the next decade at over 10 percent, and CEO Amodei has called on the industry to slow its pace and implement self-regulation.1
评论
还没有评论，欢迎留下第一条。